Abstract

 For adults with bipolar I disorder, the second-generation antipsychotic injectable drug aripiprazole is less costly and more effective over a patient’s lifetime, compared to the second-generation antipsychotic oral drug cariprazine. For adults with bipolar I disorder, aripiprazole injections are more effective compared to the second-generation antipsychotic oral drug asenapine; the cost-effectiveness over a patient’s lifetime depends on the willingness to pay. These results are based on 1 economic evaluation.
 No cost-effectiveness studies were found comparing second-generation to first-generation antipsychotic injectable drugs.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
